HPRT1 and Behcet disease: Measuring mutation frequency (MF) at the hypoxanthine–guanine–phosphoribosyltransferase (HPRT) locus as an intermediate biomarker of BD carcinogenicity could be a powerful complement to traditional methods based on mortality and cancer incidence.